Mission BioCapital’s Post

We’re excited to announce a $100 million Series C financing to advance our pipeline of selective ion channel modulators as non-opioid treatments for pain and sensory hyperexcitability disorders. Our lead program targets NaV1.8, a promising approach for meaningful analgesia with a reduced risk of abuse. We are also excited to explore the potential of sodium channels and other genetically and clinically validated targets to treat pain and sensory hyperexcitability disorders. Thank you to our investors: Novo Holdings for leading the round, and OrbiMed, Wellington Management, Mission BioCapital, BSQUARED Capital Inc., and our existing investors for participating. Read the press release here: https://lnkd.in/gSFhUNc9 We also launched a new website! Learn more about how we're "owning the action potential" to deliver innovative therapies: https://lnkd.in/gWFt3pQk #nonopioidtherapies #painmanagement #pain #drugdiscovery #ionchannels #biotech #bayarea #financing #venturecapital

InVitria, Inc. is attending #ASGCT24 in Baltimore! We will be located at Booth 131. Stop by to learn how our sustainable recombinant technology has been implemented by #celltherapy and #genetherapy developers to enhance biomanufacturing and final formulation! Connect with us through the event meeting portal to schedule a meeting. Team Members attending include: Andrew Hamann, PhD, Mark Stathos, Ph.D., Jake Hanks, Marcus Curl, Elliott Renft, Colin Odishoo, and Scott Deeter. Here's how InVitria's innovations contribute to success: Sustainability A steadfast focus on reducing the environmental impact and ensuring a sustainable and ethical supply of critical components for clinical applications. Safety and Quality Our commitment to animal-free components significantly reduces the risk of contaminants and ensures higher manufacturing consistency. Performance Enhanced cell growth, productivity, and product yield, facilitating faster and more efficient production cycles. We believe these solutions are pivotal to a future where cell and gene therapy achieve their promise for patients. They are not just a step towards more ethical and sustainable practices but also a leap towards more reliable and efficient therapeutic production. #SustainableSolutions #CellTherapies #GeneTherapies #AnimalFree #CharmCity

🚨 𝗡𝗲𝘄 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲: (𝗔𝗦𝗫: 𝗣𝗜𝗤) | 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀 𝗟𝘁𝗱. 🚨 We're excited to initiate coverage on Proteomics International Laboratories (ASX: PIQ), a biotech company commercializing cutting-edge diagnostic tests. We've assigned a fair valuation of 𝗔$𝟮.𝟴𝟰, representing a 𝟯𝟯𝟭% 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝘂𝗽𝘀𝗶𝗱𝗲 from the current price of A$0.66. Our valuation is based on a 𝗵𝗶𝗴𝗵𝗹𝘆 𝗰𝗼𝗻𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝘃𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵, factoring in cautious assumptions on market penetration. With its proprietary Promarker™ platform, PIQ is leading the way in diagnostics by identifying protein "fingerprints" in blood to detect diseases early. Key milestones ahead: - 𝗣𝗿𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝗗 (diabetes) targeting US commercial launch in H1 CY25 - 𝗣𝗿𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝗗 and 𝗣𝗿𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝗘𝘀𝗼 (esophageal cancer) set for Australian release This is an exciting time for PIQ with immense growth potential! 📈 👉 𝗥𝗲𝗮𝗱 𝗼𝘂𝗿 𝗱𝗲𝘁𝗮𝗶𝗹𝗲𝗱 𝟯𝟴-𝗽𝗮𝗴𝗲 𝗿𝗲𝗽𝗼𝗿𝘁: https://lnkd.in/ggdBxfNS Disclaimer: Report was posted on 8 October 2024 Richard Lipscombe James Williams Paul House Roger Moore Jacqueline Gray #biotech #diagnostics #ASX #PIQ #healthcare #investing

🦾 This year, the conversation has grown louder around the need for scalability and flexibility in CGT manufacturing to ensure the commercial viability of these therapies. As we work towards our mission of enabling widespread patient access, we're proud to have contributed to this conversation alongside industry leaders – highlighting what’s possible when innovation meets collaboration. Here's how we've contributed to the conversation this year and are helping to scale the impact of CGTs: 1️⃣ IRO® launch: https://lnkd.in/epRnmgnE  2️⃣ Collaboration with Charles River Laboratories: https://lnkd.in/gjj3P3GG  3️⃣ Collaboration with CTMC: https://lnkd.in/ecnJmryM  4️⃣ Frontrunners in automated CGT manufacturing: https://lnkd.in/dx9j3gg4  5️⃣ Exploring CGT’s future in Cell & Gene features part 1&2: https://lnkd.in/eGuMr4J3 #IRO #TheNewStandard #AccelerateProductDevelopment #ScaleYourImpact #AutomateBetterBiology

🔬 Monday Motivation: Embracing #Innovation in Biotech! 🌱 Let's kick off the week by celebrating the incredible innovations shaping our industry. Today, we're spotlighting the groundbreaking progress in #geneediting technologies, particularly CRISPR-Cas9. This powerful tool has opened new doors in #raredisease treatment, offering hope where there once was none. Why CRISPR-Cas9 Matters: Precision: Allows for targeted modifications at the #DNA level. Speed: Accelerates the development of therapies. Potential: Opens pathways to cure #genetic disorders. There are several players in this field we have our eye on, including CRISPR Therapeutics, Intellia Therapeutics, Inc., Beam Therapeutics, and Precision BioSciences, Inc. As we navigate our projects and goals, let's remember the passion that drives us. Make it a great week! #MondayMotivation #Biotech #CRISPR #GeneEditing #RareDiseases #CareerInspiration #BlueGeneSearch

Bluebird Faces Cash Gap with Breakeven Point in Sight Bluebird bio is about to run out of money. The gene therapy company reported $118.7 million in cash and equivalents on hand as of September 30, which will last into the first quarter of 2025. Executives told investors on a recent earnings call that they expect to eke out cash break even in the second half of 2025. But that’s only if the company manages to leap over the cash gap and bring in revenue for at least 40 drug products per quarter. When asked directly about how bluebird will cover the gap, CFO James Stirling pointed to Hercules. “Hercules has been a great partner for us through this and we’re in regular contact with them. It’d be premature for me to expand on [the] specific nature of those conversations but strategies to extend the runway include renegotiating key contracts and other cost initiatives, and our partnership with Hercules is key in helping move those forward.” https://lnkd.in/gMS_YZTV #aspenalert #biotech #bioprocess

Helix's CEO, Mr. Josh Carter, is actively engaging at the American Crystallographic Association's 74th Annual Meeting in Denver, Colorado, from July 7-12, 2024. Day three has been electrifying, featuring an array of exciting and highly relevant topics such as MicroED, Cryo-EM, and Structural Biology in Pharma/Biotech. Two great talks that highlight the intersection of various disciplines, including crystallization, docking, and targeting undruggable proteins, are "Novel Fragment Inhibitors of PYCR1 from Docking-Guided X-ray Crystallography" from U. Missouri, ChemSpace, and Taras Shevchenko National University of Kyiv, and "Branched Chain Ketoacid Dehydrogenase Kinase Inhibitors: From Fragments to Clinical Candidate" by Pfizer. And don’t miss the poster sessions, which are also full of groundbreaking research! Mr. Josh Carter looks forward to connecting with both familiar and new friends, clients, and colleagues, sharing Helix's contributions and insights on today's topics in these fields. Be sure to catch up with him! Did you know... Our leading Cryo-EM services, together with our extensive expertise, consistently fuel the success of our clients and their projects? Empower projects with Helix and Cryo-EM. Call us today! (https://loom.ly/SNcIRks) #cryoem #crystallization #crystallography #drugdiscovery #drugdesign #protein #proteins #dna #rna #antibody #antibodies #science #nature #research #bio #bionetwork #biotechnology #biotech #bioscience #biotechnologyindustry #biopharma #drugdesign #drugdevelopment #pharmaceuticals #pharma #drug #lifesciences #lifescience

📰 Always nice to see tenant updates in Endpoints News! Granza Bio (YC W24)'s Felicis and Refactor led $7m seed round, aided by Y Combinator, has caught its eye this time. 👨🏾🔬 👨🏾🔬 Ashwin Menon Nandakumar and Ashwin Jainarayanan, alongside academic Michael Dustin, founded the University of Oxford spin-out to develop attack particles, using the immune system to treat cancer and autoimmune diseases. ➡ Here's the article https://lnkd.in/eFMEnUwj #oxfordinnovation

How to generate high-quality, monoclonal cell populations in cell line development (CLD)? 🌟 If you're a scientist facing challenges with precise single-cell seeding, boosting cell line purity, scalability, or isolating rare cells, read this blog by Dr. Katrin Raute, PhD for success strategies that also help with regulatory compliance. 💡 Inside the Blog: ✔️ Importance of single-cell seeding ✔️ Methods to ensure traceability and regulatory compliance ✔️ Isolation of rare cells in oncology and microbiome research ✔️ Verifying cell viability and purity … and more. Access the full article now. 📖👇 https://lnkd.in/eF2iA9a4 #CellLineDevelopment #SingleCellSeeding #HealthCareInnovation #Biotech #Blog

🧠💡 Dive further into the conversation between Dan Doctoroff and our CEO, Stella Sarraf, PhD, about the diverse symptoms of #ALS and why Spinogenix is developing therapeutics that work at ground zero: the synaptic level. We believe that #RegeneratingSynapses is key to transforming lives. That’s why we are developing a platform of small molecules that aim to restore #Synapses for diseases involving synapse loss and dysfunction. Stay tuned for more insights into our shared mission to advance #ALSResearch.